Olynth HA 0.1% nasal spray

Olynth is a well-known brand of nasal decongestants widely used across Europe to treat symptoms of the common cold and sinusitis. The brand was originally developed in Germany by Gödecke AG (later acquired by Pfizer and subsequently Johnson & Johnson).

Today, Olynth is part of the Kenvue portfolio, a specialized consumer health company that spun off from Johnson & Johnson in 2023. Kenvue is headquartered in the United States and operates as an independent global entity. Manufacturing for the European market, including the HA 0.1% variant with hyaluronic acid, is often handled at specialized facilities in France (such as the Val de Reuil site), though production can occur across multiple global locations depending on regional supply chains.